Scientists assert that the lungs are more susceptible to infection by new coronavirus strains, such as the BA4 and BA5 substrains of Omicron.
The effects of the intranasally administered Sputnik V coronavirus vaccination on animals have been shown by a recent study by the Russian Direct Investment Fund and the Gamaleya National Research Center of Epidemiology and Microbiology.
The vaccination triggers a potent and long-lasting immunological response in animals, the Russian research institute reported on Wednesday. The journal Emerging Microbes & Infections published the results of the most recent study.
“Mice and non-human primates were used in the study of the intranasal Sputnik V.” (common marmosets). Antigen-specific T-cell proliferation marked IgG and neutralizing antibody (NtAb) synthesis in blood serum, and the development of IgA antibodies in the nasal mucosa were all indicators of the vaccine’s high immunogenicity. The vaccine triggered a significant local and systemic immune response that lasted for at least 180 days. The research institute said in a statement on Wednesday that the results “show that in the mouse model, intranasal and intramuscular administration of Sputnik V vaccine elicit comparable magnitude of central antigen-specific immunity, while only intranasal vaccination forms humoral and cell-mediated response in lungs.
Scientists assert that the lungs are more susceptible to infection by new coronavirus strains, such as the BA4 and BA5 substrains of Omicron.
The Russian institute asserted that the intranasal injection of Sputnik V is equally effective as the originally produced intramuscular vaccination at promoting local and systemic immune responses as well as protection against deadly virus challenges.
Sputnik Light and V have currently received approval from more than 30 nations each, respectively.
